The German pharmaceutical and technology group Merck recorded an attributable profit of 2,608 million euros in 2025, a drop of 6% compared to 2024, in a context of geopolitical challenges and unfavorable exchange rates.
Merck reported this Thursday, 55, that revenue fell in the last fiscal year to 21,102 million euros (-0.3% compared to 2024), having slipped 3.1% in the fourth quarter.
Exchange rates had a negative effect of 3.7% due to the strength of the dollar and several Asian currencies.
The acquisition of SpringWorks and the sale of Surface Solutions had a positive effect on revenue of 0.4%.
Operating profit fell in the last fiscal year to R$3,601 million (-1.2%).
“Once again, in 2025, we demonstrated our resilience in the face of significant geopolitical challenges and severe exchange rate pressures,” said the chairman of the Board of Directors and executive president, Belén Garijo, when presenting the results.
Merck’s management and Supervisory Board will propose the distribution of a dividend of R$2.20 per share.
Merck forecasts revenues of between 20,000 and 21,100 million euros for 2026 and earnings before interest, taxes, depreciation and amortization (EBITDA) of between 5,500 and 6,000 million euros (6,100 million euros in 2025).
These forecasts take into account that, from March 2026, there will be no sales of its multiple sclerosis drug Mavenclad in the USA due to generic competition and exclude the positive effects of the launch in the USA of Pergoveris, a drug for assisted reproduction treatments.
Leave a Reply